NSE: LUPIN · 26 October 2026
- Lupin Limited shares advanced 1.61% today, recovering from a recent stretch of weakness. The stock opened at ₹1,924.10 and moved within a day's range of ₹1,912.40 to ₹1,959.90, eventually settling near the high at ₹1,959.90.
- Lupin informed the exchanges that the U.S. FDA concluded an inspection at its manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026, and concluded with the issuance of a Form-483 carrying one observation. The company stated it will address the observation and respond to the regulator within the stipulated timeframe.
- Trading volume was 0.65 times the 20-day average daily volume.
Why is LUPIN share price rising on 26 October 2026?
Lupin Limited shares advanced 1.61% today, recovering from a recent stretch of weakness. The stock opened at ₹1,924.10 and moved within a day's range of ₹1,912.40 to ₹1,959.90, eventually settling near the high at ₹1,959.90.
The broader market and sector backdrop provided strong supportive momentum for the pharmaceutical major. The benchmark Nifty rose 0.68%, while the Nifty Pharma sector index outperformed with a 1.76% gain, reflecting broad-based buying interest across healthcare stocks.
On the corporate front, recent developments include the U.S. FDA concluding an inspection at the company's manufacturing facility in Goa on October 23, 2026, which resulted in a Form-483 with one observation. Additionally, the company appointed Brian Savage as President and Chief Legal Officer effective October 22, 2026. While these operational and management updates provide broader context regarding regulatory progression and corporate governance, today's price action appears largely aligned with broader sector strength and a technical recovery following a 20-day return decline of 6.70%.
4.46 lakh shares traded by 26 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.88 lakh shares (0.65 times). The five-day average daily volume was 6.79 lakh shares. Separately, the NSE report for 26 October 2026 showed 2.31 lakh shares delivered, representing 51.84% of that day’s traded volume. The same report recorded 35,388 trades.
Today's 1.61% gain occurred on below-average volume and lacks an explicit same-day corporate catalyst. The upward movement aligns with broader strength in the Nifty Pharma sector and represents a technical rebound following recent multi-week underperformance.
Latest Company Developments
Lupin informed the exchanges that the U.S. FDA concluded an inspection at its manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026, and concluded with the issuance of a Form-483 carrying one observation. The company stated it will address the observation and respond to the regulator within the stipulated timeframe.
Regulatory inspections and observations at key manufacturing sites are critical for maintaining continuous export visibility and compliance standards in regulated markets.
Lupin announced the appointment of Brian Savage as President and Chief Legal Officer, effective October 22, 2026. Savage will lead the company's global Legal, Compliance, and Intellectual Property Management Group functions, operating from New Jersey. He brings extensive industry experience, having previously served in senior legal leadership roles at Teva Pharmaceuticals.
Strengthening executive leadership in legal and compliance functions supports the company's governance framework as it navigates complex global regulatory landscapes.
Lupin announced it received approval from the U.S. FDA for its Phytonadione Injectable Emulsion, USP, 1 mg/0.5 mL single-dose ampuls. The product is a generic equivalent of AquaMEPHYTON Injectable Emulsion and will be manufactured at Lupin's facility in Nagpur, India. The product addresses specific therapeutic requirements in the U.S. market.
Regulatory approvals for complex or generic formulations expand the company's U.S. product pipeline and support ongoing revenue growth in key international markets.
Lupin Limited has informed the Exchange that U.S. FDA has concluded an inspection at our manufacturing facility located in Goa, India.
a press release dated October 08, 2026, titled "Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.58% on 30 September 2026. This compares with 14.84% on 30 June 2026, a change of -0.26 percentage points.
The filing reported 43 MF/UTI holders.
Historical Bulk / Block Deals
Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com
What to Watch Next
- Upcoming announcement of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, scheduled for November 3, 2026
- Company response and remediation progress regarding the U.S. FDA Form-483 observation at the Goa manufacturing facility
- Execution and commercial rollout of recently approved products such as Phytonadione Injectable Emulsion in the U.S. market
- Delivery volumes and cash market participation relative to the 20-day average volume benchmark
Other Dated Coverage
- LUPIN Share Price Today: Why LUPIN Is Falling 0.01% | 23 October 2026 — 23 October 2026
- LUPIN Share Price Today: Why LUPIN Is Falling 2.14% | 22 October 2026 — 22 October 2026
- Lupin in Focus Today Following Independent FY26 ESG Rating Assignment | 16 October 2026 — 16 October 2026
More LUPIN news and dated analysis →
Frequently Asked Questions
What is the latest LUPIN company news?
Lupin informed the exchanges that the U.S. FDA concluded an inspection at its manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026, and concluded with the issuance of a Form-483 carrying one observation. The company stated it will address the observation and respond to the regulator within the stipulated timeframe.
How strong was LUPIN’s trading volume?
4.46 lakh shares traded, 0.65 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.